For instance, efforts are being made to elucidate the role of tumor mutational burden, programmed death-ligand 1 (PD-L1) expression, and other potential biomarkers in predicting patient responses to checkpoint inhibitors and other immunotherapies [29]. Here, CD274 is linked to neoplasm.